EUCTR2008-001784-11-DE进行中（未招募）不适用
A Phase 2, Double-Blind, Placebo-Controlled Study of Uro-Vaxom® for the Management of Uncomplicated Recurrent Urinary Tract Infections - A Study of Two Doses of Uro-Vaxom® for the Management of Recurrent Urinary Tract Infections
Alita Pharmaceuticals, Inc.0 个研究点目标入组 420 人开始时间: 2008年6月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •A patient must meet the following criteria at Screening (Visit 1) to participate in this study:
- •I.1 Ambulatory female aged 18 to 73 years
- •I.2 Acute uncomplicated UTI at Screening, including at least one of the following symptoms persisting for at least one day: dysuria, increased frequency, increased urgency, or suprapubic pain
- •I.3 If of child-bearing potential, must agree to use an adequate, consistent form of contraception during the study [e.g., oral contraceptives or hormone-containing intra-uterine device use during the study at the same dose and regimen and for at least 90 days prior to study start; abstinence, sterilization of self or partner, or any other contraceptive method(s) not prohibited by the protocol with a Pearl index < 1 (a Pearl index of 1 corresponds to 1 woman out of 100 women becoming pregnant within 1 year using the same method of contraception)]
- •I.4 Written informed consent
- •A patient must also meet the following additional criteria at Randomization (Day 0/Visit 2) to participate in this study:
- •I.5 Acute uncomplicated UTI at Screening must have included a clean-catch midstream bacterial count of =10^3 CFU/mL of at least one species
- •I.6 History of recurrent UTI:
- •a. For patients not requiring a Qualification Period: 3 qualifying, documented UTIs in the year prior to Randomization (Day 0) OR
- •b. For patients requiring a Qualification Period: 2 qualifying, documented UTIs in the 120 days prior to Randomization (Day 0)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A patient will be excluded from participating in the study at Screening (Visit 1) and unless noted otherwise, Randomization (Day 0/Visit 2) for any of the following reasons:
- •E.1 History of more than 10 UTIs in the year before Screening meeting the documented historical UTI definition
- •E.2 Long-term (>30 days continuous therapy) or frequent intermittent (>14 days/month for a non-UTI indication) anti-infective use in the 90 days before Screening
- •E.3 History of interstitial cystitis, inflammatory bowel disease, or chronic enteropathies
- •E.4 Functional and structural abnormalities within the urinary tract or obstructive morphological changes as documented in the patient’s medical history
- •E.5 History of persistent UTIs (i.e., history of at least 2 UTIs meeting the documented historical UTI definition lasting = 14 days in the year prior to Screening)
- •E.6 Use of a urinary catheter within 90 days prior to Screening, however, transient (in and out”) catheterization by a qualified medical professional using accepted catheterization techniques (i.e., perineal preparation) for the purposes of collection of an adequate bladder sample is acceptable
- •E.7 Known symptoms of neurogenic bladder dysfunction, as manifested either by the presence of a neurological condition (e.g., spinal cord injury) that is associated with neurogenic bladder dysfunction or known abdominal urodynamic studies (voiding cystourethrogram, cystometry) consistent with the diagnosis of neurogenic bladder dysfunction
- •E.8 Abnormal clinically significant laboratory values, as determined by the investigator, at Screening
- •E.9 Severe cardiovascular disease (e.g., left ventricular failure, stroke)
- •E.10 Significant liver insufficiency — i.e., AST and ALT > 2xULN
- •E.11 Renal disease, pyelonephritis, or significant renal insufficiency (i.e., serum creatinine > 1.5 mg/dL [133 µmol/L])
- •E.12 Malignant disease within 5 years of entering the study (excluding basal cell carcinoma of the skin, carcinoma in situ of the uterine cervix treated with cryosurgery or conization, or isolated cutaneous melanomas <5 mm in the longest diameter)
- •E.13 Active autoimmune disease and other systemic diseases related to immune system disorders (except diabetes mellitus with controlled blood glucose levels during the 90 days prior to Screening, as determined by the investigator)
- •E.14 Pregnant, lactating, or planning to become pregnant
- •E.15 Unreliable or non-compliant, including patients with known history of alcoholism, drug abuse, or serious psychiatric disorder; as well as patients unwilling to abide by the requirements of the protocol
- •E.16 Major surgical procedure, registered pharmaceutical immunomodulatory therapy for indications other than UTI, use of any experimental drug or device, or participation in another clinical trial within the 90 days prior to Screening
- •E.17 Exposure to any registered pharmaceutical immunomodulatory therapy for UTI [e.g., Uro-Vaxom® (also known as OM-89/OM-89S/AP-89) or StroVac®] or Subreum® within 1 year prior to Screening
- •E.18 Anticipated antibiotic use during the study, except for the treatment of acute UTI
- •E.19 Use of hormone replacement therapy or cranberry products for less than the 90 days prior to Screening. [Use of these products is allowed IF the dose and regimen remain constant at least 90 days before Screening and for the duration of the study.]
- •E.20 Any condition, as determined by the investigator, that would interfere with the patient’s ability to c
研究者
相似试验
进行中（未招募）
不适用
A study in patients with chondrosarcoma comparing IPI-926 to placeboEUCTR2010-024518-74-ESInfinity Pharmaceuticals, Inc169
进行中（未招募）
1 期
A study in patients with chondrosarcoma comparing IPI-926 to placeboMetastatic or Locally Advanced ChondrosarcomaMedDRA version: 14.1Level: PTClassification code 10008734Term: ChondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024518-74-GBInfinity Pharmaceuticals, Inc105
进行中（未招募）
不适用
A study in patients with chondrosarcoma comparing IPI-926 to placeboMetastatic or Locally Advanced ChondrosarcomaMedDRA version: 14.1Level: PTClassification code 10008734Term: ChondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024518-74-NLInfinity Pharmaceuticals, Inc140
进行中（未招募）
不适用
A study in patients with chondrosarcoma comparing IPI-926 to placeboMetastatic or Locally Advanced ChondrosarcomaMedDRA version: 14.0Level: PTClassification code 10008734Term: ChondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024518-74-DEInfinity Pharmaceuticals, Inc140
已完成
2 期
A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients with Metastatic or Locally Advanced (Unresectable) ChondrosarcomaNL-OMON38109Infinity Pharmaceuticals, Inc.10